Promega Introduces New Mass Spec Reagents, IdeS Protease and Human and Yeast Protein Extracts
Promega Corporation announces the launch of new products for scientists working with mass spectrometry. The IdeS Protease enables fast, easy, high performance digestion of immunoglobulin, while the Human and Yeast Protein Extracts provide a test material for optimizing mass spec sample preparation. The new products add to the company’s existing range of proteases and services to improve mass spec sample prep workflows.
IdeS Protease is a recombinant, engineered version of the immunoglobulin-degrading enzyme from Streptococcus pyogenes. It is a highly specific protease that slices Immunoglobulin G (IgG) at a single, targeted site, offering 100% digestion in 30 minutes with no optimization. IdeS can be used to characterize therapeutic antibody candidates using LC/MS, and contains a histidine tag for easy removal. The versatile Promega IdeS enzyme cuts IgGs from a range of species, as well as Fc-fusion proteins.
The new yeast and human protein extracts are designed specifically for mass spectrometry applications. Available in either predigested, cleaned form for immediate use in LC/MS analysis or intact, undigested form to provide a test material for optimizing mass spec protein sample preparation, the extracts provide clean, consistent, quantified, model system samples for LC/MS method development and instrument monitoring. The yeast extracts are beneficial for users who prefer working with a relatively compact and well-studied proteome, whereas the human extract, with large dynamic range, provides the opportunity to work with complex proteomes. The new products are: MS Compatible Yeast Protein Extract, Digest; MS Compatible Human Protein Extract, Digest; MS Compatible Yeast Protein Extract, Intact; and MS Compatible Human Protein Extract, Intact.
Related News
-
News Novartis signs US$3.2 bn subcutaneous delivery deal with Alteogen
Swiss pharma giant secures access to Korean biotech's ALT-B4 hyaluronidase platform in milestone-heavy agreement, marking Alteogen's fourth major licensing deal of 2026 as competition intensifies in the subcutaneous drug delivery space.
-
News Women in Pharma: The philosophy of pharmaceutical leadership
In this latest instalment of our Women in Pharma series, we sit down with Clarissa Sowemimo-Coker, Chief Strategy Officer at Ambrose Healthcare and CPHI Middle East Advisory Board Member.
-
News The PSCI Supplier Partnership - Collaboration for Responsible Supply Chains
About the Pharmaceutical Supply Chain Initiative The Pharmaceutical Supply Chain Initiative (PSCI) is the leading, member-led association for pharmaceutical companies working collaboratively to build responsible supply chains. Founded in 2006 and es... -
News AstraZeneca shares plunge 8.9% after reports of BMS talks
Britain's largest drugmaker lost more than GBP£17 billion in market value following reports of preliminary merger discussions with Bristol Myers Squibb that could create a pharmaceutical giant worth nearly US$400 billion, though investors rem... -
News GSK announces £400 million investment in new Cambridge R&D centre
Pharmaceutical giant to establish flagship research facility on Cambridge Biomedical Campus as part of strategic pipeline acceleration
-
News The CPHI Sustainability Summit - Where Conversation Becomes Collaboration
The Report Was Never the Destination - “The future of pharmaceutical sustainability won’t be shaped by individual organisations working in isolation. It will be shaped by partnerships, shared expertise and the willingness to work diffe... -
News Trump's generic drug tariffs set to reshape global pharmaceutical supply chains
The US president has announced plans to impose tariffs of up to 200% on imported generic medicines from August 2028, giving manufacturers a two-year window to establish domestic production facilities. The move threatens to upend a global supply chain t... -
News Building Safer, More Responsible Pharmaceutical Supply Chains: PSCI Global Audit Insights
The Pharmaceutical Supply Chain Initiative (PSCI) has released its seventh annual Audit Findings Analysis Report, offering unprecedented insights into supplier practices across the global pharmaceutical and healthcare industry.With a record-breaking 24...